MedTrace Logo

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

NCT05324501 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2025-02-10

No results posted yet for this study

Summary

A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

Conditions

Interventions

DRUG

MTX110

Soluble panobinostat

DEVICE

Programmable pump and catheter system

To allow Convection-Enhanced Delivery (CED)

Sponsors & Collaborators

  • Biodexa Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gary Shangold · Biodexa Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-19
Primary Completion
2024-09-10
Completion
2024-09-10
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05324501 on ClinicalTrials.gov